AstraZeneca released updated information on its COVID-19 clinical trial Wednesday evening, showing an effectiveness rate of 76% instead of the 79% rate it claimed earlier in the week.
On Monday, the company, which has developed its vaccine in collaboration with scientists at Oxford University, released interim data from a 32,000-person trial conducted this winter in the U.S., Chile and Peru.
As of Feb. 17, 141 people in the trial had come down with COVID-19, the vast majority in the group that received a salt-water placebo rather than the active vaccine. Among those people, the vaccine was shown to 79% effective in preventing any symptoms of COVID-19 and 100% effective in preventing severe disease and hospitalizations.
Send an email
